Tonix Pharmaceuticals Publishes Steady-State Pharmacokinetics Data for TONMYA in Fibromyalgia Treatment — Tonix Pharmaceuticals Holding Corp.

Event summary

Tonix Pharmaceuticals published steady-state pharmacokinetics data for TONMYA in the journal Clinical Pharmacology in Drug Development on April 15, 2026.
The study demonstrated that TONMYA's sublingual formulation achieves higher bioavailability and earlier peak plasma concentrations compared to oral extended-release cyclobenzaprine.
TONMYA was approved by the FDA for fibromyalgia treatment in August 2025 and commercially launched in November 2025.
The study involved 60 healthy adult volunteers and showed that TONMYA is generally safe and well-tolerated over 20 days of daily dosing.

The big picture

Tonix Pharmaceuticals' publication of steady-state pharmacokinetics data for TONMYA underscores its strategic focus on differentiating its fibromyalgia treatment through superior drug delivery mechanics. The study's findings support the company's claims of improved bioavailability and targeted sleep-phase efficacy, which are critical in a market where patient dissatisfaction with existing treatments is high. This move aligns with broader industry trends toward precision pharmacokinetics and long-term safety profiling for chronic conditions.

What we're watching

Market Differentiation: Whether TONMYA's unique pharmacokinetic profile can sustain a competitive edge in the fibromyalgia treatment market.
Regulatory Compliance: The pace at which Tonix can address potential regulatory hurdles related to long-term use of TONMYA.
Commercialization Strategy: How Tonix will leverage this data to enhance the commercialization and adoption of TONMYA among physicians and patients.